Can you review the latest clinical trials and over-the-counter preventative regimens for treating recurrent yeast infections that seem resistant to standard oral fluconazole therapy?
Download run
Fan-out diagram
The searches the AI actually ran for this prompt.
SEED QUERY
Can you review the latest clinical trials and over-the-counter preventative regimens for treating recurrent yeast infections that seem resistant to standard oral fluconazole therapy?
3 real searches · 1 real-search pass
recurrent vulvovaginal candidiasis fluconazole resistant clinical trials 2025 2026 oteseconazole ibrexafungerp phase 3Google ↗
OBSERVED
CDC vulvovaginal candidiasis recurrent non-albicans boric acid probiotics guideline culture susceptibilityGoogle ↗
OBSERVED
clinical trial recurrent vulvovaginal candidiasis 2025 2026 novel treatment trialGoogle ↗
OBSERVED
Badge and edge weight = share of passes that produced the query. Hover a query for its intent and routing format.
Query classes
Google's semantic query class for every sub-query: what kind of answer each search is after, simulated vs real.
Classifying 3 queries…
Searches and sources
ChatGPT3 real searches · gpt-6
recurrent vulvovaginal candidiasis fluconazole resistant clinical trials 2025 2026 oteseconazole ibrexafungerp phase 3 Google ↗
CDC vulvovaginal candidiasis recurrent non-albicans boric acid probiotics guideline culture susceptibility Google ↗
clinical trial recurrent vulvovaginal candidiasis 2025 2026 novel treatment trial Google ↗
- Vulvovaginal Candidiasis · cdc.gov
- A phase 3, multicenter, randomized, placebo-controlled trial of monthly oral ibrexafungerp to reduce the incidence of recurrent vulvovaginal candidiasis · pubmed.ncbi.nlm.nih.gov
- Study Details | NCT05399641 | Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis · clinicaltrials.gov
- LABEL · accessdata.fda.gov
- Oteseconazole for acute and recurrent vulvovaginal candidiasis: A systematic review, meta-analysis, and trial sequential analysis of randomized trials. · pubmed.ncbi.nlm.nih.gov
- These highlights do not include all the information needed to use VIVJOA™ safely and effectively. See full prescribing information for VIVJOA™. VIVJOA™ (oteseconazole) capsules, for oral use Initial U.S. Approval: 2022 · dailymed.nlm.nih.gov
- Drug Trials Snapshots: VIVJOA · fda.gov
- Safety and Efficacy of Boric Acid Inserts for Treatment of Vulvovaginal Candidiasis · centerwatch.com
- Boric acid in Vulvovaginal Candidiasis, Genital and Vulvovaginal Candidiases and Vulvovaginal Candidiasis (VVC) - Clinical Trials Registry · ichgcp.net
Queries
3 queries · click a column to sort
| Query / type | Search | Intent | Query class | Routing format | Cluster | Freq ↓ | Weight |
|---|---|---|---|---|---|---|---|
recurrent vulvovaginal candidiasis fluconazole resistant clinical trials 2025 2026 oteseconazole ibrexafungerp phase 3 OBSERVED | Google ↗ AI Mode ↗ | — | — | — | — | 1x of 1 | |
CDC vulvovaginal candidiasis recurrent non-albicans boric acid probiotics guideline culture susceptibility OBSERVED | Google ↗ AI Mode ↗ | — | — | — | — | 1x of 1 | |
clinical trial recurrent vulvovaginal candidiasis 2025 2026 novel treatment trial OBSERVED | Google ↗ AI Mode ↗ | — | — | — | — | 1x of 1 |